S

Sanofi

Global pharma company; vaccines and R&D

Refrigeration Facilities Operator

Full-TimeUpdated on 10/23/2026Deadline 11/6/26
$54.52/hr
Mid
Toronto, ON, Canada
In PersonOnsite in Toronto; Monday–Friday, 7:00 a.m.–3:00 p.m.
Building TradesHVAC & Building Systems

About the job

Requirements
  • A high school diploma is required.
  • A minimum four-year accredited certificate program, a millwright license, and a valid Ontario Refrigeration Certificate are required.
  • A minimum of four years of previous relevant work experience is required.
  • Knowledge of mechanical and electrical systems, troubleshooting, blueprint reading, and computer applications or systems is required.
  • Strong verbal and written communication skills and interpersonal and teamwork skills are required.
  • The role requires working Monday through Friday, 7:00 a.m. to 3:00 p.m.; these hours may change to meet operational requirements.
Responsibilities
  • Operate building systems, Building Automation Systems (BAS), and Facility Management Systems (FMS) to provide reliable environmental conditions and utilities for production, packaging, laboratory, warehouse, and office areas; monitor systems, address alarms and known issues, and document system conditions.
  • Operate equipment on Building Automation Systems; maintain and troubleshoot equipment and systems; document and log equipment and system conditions; and inform the manager, Quality, and customers of abnormal conditions and corrective actions taken or needed.
  • Monitor FMS and BAS for proper equipment operation and respond to or identify Good Manufacturing Practice (GMP) and business-critical alarms within the required timeframe.
  • Respond to alarms and perform repairs and troubleshooting to resolve alarm conditions; coordinate with other trades, engineering, and contractors as needed; advise the manager, Quality, and customers of corrective and preventive actions; update alarm tag notes; and document information in the work order system.
  • Troubleshoot refrigeration systems, heating, ventilation, and air conditioning (HVAC), clean utilities, steam, plumbing, and other building systems and facilities; provide repairs and rechecks where urgency, expertise, or licensing permits; and perform repairs that do not require a specialized license.
  • Coordinate with other trades, engineering, contractors, and stores to complete work in a timely manner; use drawings and manuals for troubleshooting; and provide issue updates to the manager, Quality, and customers.
  • Perform assigned preventive maintenance and daily or weekly equipment checks using the SAP work order system, where not restricted by regulatory licensing requirements; identify and request required parts; keep work areas tidy; and monitor mechanical rooms for cleanliness, leaks, and other abnormal conditions, performing repairs as needed.
  • Determine the impact of work and coordinate major repairs and scheduled or unscheduled facility and equipment shutdowns with trade staff, contractors, users, planners, customers, and building managers to minimize service interruptions.
  • Review major planned shutdown work orders with the planner using SAP, coordinate with stores to ensure parts are available, and assist in arranging external contractors for shutdown work.
  • Perform other assigned duties, including continuous improvement, projects, initiatives, and tasks needed to operate the business.
Desired Qualifications
  • A four-year accredited certificate program with a valid Ontario Refrigeration Certificate and at least four years of relevant experience is listed as preferred.
  • A four-year accredited certificate program with a valid Ontario Refrigeration Certificate, another Ontario or interprovincial ticket or certification, and at least three years of relevant experience is listed as preferred.
  • Experience or knowledge in HVAC, mechanical or electrical systems, building automation systems, and troubleshooting equipment in a GMP-regulated facility or laboratory is preferred.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Company News

Associated Press
Oct 19th, 2026
Enable Injections wins first Japan approval for enFuse on-body injector via Sanofi's CirCLIQ

Enable Injections has won its first commercial product approval in Japan. The country's Ministry of Health, Labour and Welfare approved the company's enFuse On-Body Delivery System through Sanofi's CirCLIQ Injector. The device delivers a subcutaneous form of Sarclisa (isatuximab) with the push of a button, for treating multiple myeloma. It is the first anticancer treatment given through an on-body injector in Japan. The approval follows recent clearances in the US and Europe. Japan approved Sarclisa SC in June 2026, backed by the IRAKLIA phase 3 study, which showed the subcutaneous form was non-inferior to intravenous delivery. "We're proud to partner with Sanofi to bring our enFuse technology to patients in Japan," said Michael D. Hooven, chairman and chief executive officer of Enable.

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...